PARP inhibitor receives FDA breakthrough therapy designation in castration resistant prostate cancer: beyond germline BRCA mutations-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

PARP inhibitor receives FDA breakthrough therapy designation in castration resistant prostate cancer: beyond germline BRCA mutations

Published:2016-05 Issue:5 Volume:27 Page:755-757
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Helleday T.

Funder

Knut and Alice Wallenberg Foundation

Swedish Research Council

European Research Council

Swedish Cancer Society

Swedish Children's Cancer Foundation

Swedish Foundation for Strategic Research

Swedish Pain Relief Foundation, AFA foundation

Torsten and Ragnar Söderberg Foundation

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference16 articles.

1. DNA-repair defects and olaparib in metastatic prostate cancer;Mateo;N Engl J Med,2015

2. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer;Welcsh;Hum Mol Genet,2001

3. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose)polymerase;Bryant;Nature,2005

4. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy;Farmer;Nature,2005

5. Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair;Bryant;Nucleic Acids Res,2006

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer;Oncogene;2024-09-13

2. The Cost-Effectiveness of Germline BReast CAncer Gene Testing in Metastatic Prostate Cancer Followed by Cascade Testing of First-Degree Relatives of Mutation Carriers;Value in Health;2024-07

3. AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer;2024-05-07

4. The cost-effectiveness of germline BRCA testing-guided olaparib treatment in metastatic castration resistant prostate cancer;International Journal of Technology Assessment in Health Care;2024

5. Characterizing Referrals for Prostate Cancer Genetic Services in a Safety-Net Hospital;JCO Oncology Practice;2023-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3